Cargando…

Evaluation of Clinical Risk Factors to Predict High On-Treatment Platelet Reactivity and Outcome in Patients with Stable Coronary Artery Disease (PREDICT-STABLE)

OBJECTIVES: This study was designed to identify the multivariate effect of clinical risk factors on high on-treatment platelet reactivity (HPR) and 12 months major adverse events (MACE) under treatment with aspirin and clopidogrel in patients undergoing non-urgent percutaneous coronary intervention...

Descripción completa

Detalles Bibliográficos
Autores principales: Droppa, Michal, Tschernow, Dimitri, Müller, Karin A. L., Tavlaki, Elli, Karathanos, Athanasios, Stimpfle, Fabian, Schaeffeler, Elke, Schwab, Matthias, Tolios, Alexander, Siller-Matula, Jolanta M., Gawaz, Meinrad, Geisler, Tobias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4370634/
https://www.ncbi.nlm.nih.gov/pubmed/25799149
http://dx.doi.org/10.1371/journal.pone.0121620
_version_ 1782362905190072320
author Droppa, Michal
Tschernow, Dimitri
Müller, Karin A. L.
Tavlaki, Elli
Karathanos, Athanasios
Stimpfle, Fabian
Schaeffeler, Elke
Schwab, Matthias
Tolios, Alexander
Siller-Matula, Jolanta M.
Gawaz, Meinrad
Geisler, Tobias
author_facet Droppa, Michal
Tschernow, Dimitri
Müller, Karin A. L.
Tavlaki, Elli
Karathanos, Athanasios
Stimpfle, Fabian
Schaeffeler, Elke
Schwab, Matthias
Tolios, Alexander
Siller-Matula, Jolanta M.
Gawaz, Meinrad
Geisler, Tobias
author_sort Droppa, Michal
collection PubMed
description OBJECTIVES: This study was designed to identify the multivariate effect of clinical risk factors on high on-treatment platelet reactivity (HPR) and 12 months major adverse events (MACE) under treatment with aspirin and clopidogrel in patients undergoing non-urgent percutaneous coronary intervention (PCI). METHODS: 739 consecutive patients with stable coronary artery disease (CAD) undergoing PCI were recruited. On-treatment platelet aggregation was tested by light transmittance aggregometry. Clinical risk factors and MACE during one-year follow-up were recorded. An independent population of 591 patients served as validation cohort. RESULTS: Degree of on-treatment platelet aggregation was influenced by different clinical risk factors. In multivariate regression analysis older age, diabetes mellitus, elevated BMI, renal function and left ventricular ejection fraction were independent predictors of HPR. After weighing these variables according to their estimates in multivariate regression model, we developed a score to predict HPR in stable CAD patients undergoing elective PCI (PREDICT-STABLE Score, ranging 0-9). Patients with a high score were significantly more likely to develop MACE within one year of follow-up, 3.4% (score 0-3), 6.3% (score 4-6) and 10.3% (score 7-9); odds ratio 3.23, P=0.02 for score 7-9 vs. 0-3. This association was confirmed in the validation cohort. CONCLUSIONS: Variability of on-treatment platelet function and associated outcome is mainly influenced by clinical risk variables. Identification of high risk patients (e.g. with high PREDICT-STABLE score) might help to identify risk groups that benefit from more intensified antiplatelet regimen. Additional clinical risk factor assessment rather than isolated platelet function-guided approaches should be investigated in future to evaluate personalized antiplatelet therapy in stable CAD-patients.
format Online
Article
Text
id pubmed-4370634
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-43706342015-04-04 Evaluation of Clinical Risk Factors to Predict High On-Treatment Platelet Reactivity and Outcome in Patients with Stable Coronary Artery Disease (PREDICT-STABLE) Droppa, Michal Tschernow, Dimitri Müller, Karin A. L. Tavlaki, Elli Karathanos, Athanasios Stimpfle, Fabian Schaeffeler, Elke Schwab, Matthias Tolios, Alexander Siller-Matula, Jolanta M. Gawaz, Meinrad Geisler, Tobias PLoS One Research Article OBJECTIVES: This study was designed to identify the multivariate effect of clinical risk factors on high on-treatment platelet reactivity (HPR) and 12 months major adverse events (MACE) under treatment with aspirin and clopidogrel in patients undergoing non-urgent percutaneous coronary intervention (PCI). METHODS: 739 consecutive patients with stable coronary artery disease (CAD) undergoing PCI were recruited. On-treatment platelet aggregation was tested by light transmittance aggregometry. Clinical risk factors and MACE during one-year follow-up were recorded. An independent population of 591 patients served as validation cohort. RESULTS: Degree of on-treatment platelet aggregation was influenced by different clinical risk factors. In multivariate regression analysis older age, diabetes mellitus, elevated BMI, renal function and left ventricular ejection fraction were independent predictors of HPR. After weighing these variables according to their estimates in multivariate regression model, we developed a score to predict HPR in stable CAD patients undergoing elective PCI (PREDICT-STABLE Score, ranging 0-9). Patients with a high score were significantly more likely to develop MACE within one year of follow-up, 3.4% (score 0-3), 6.3% (score 4-6) and 10.3% (score 7-9); odds ratio 3.23, P=0.02 for score 7-9 vs. 0-3. This association was confirmed in the validation cohort. CONCLUSIONS: Variability of on-treatment platelet function and associated outcome is mainly influenced by clinical risk variables. Identification of high risk patients (e.g. with high PREDICT-STABLE score) might help to identify risk groups that benefit from more intensified antiplatelet regimen. Additional clinical risk factor assessment rather than isolated platelet function-guided approaches should be investigated in future to evaluate personalized antiplatelet therapy in stable CAD-patients. Public Library of Science 2015-03-23 /pmc/articles/PMC4370634/ /pubmed/25799149 http://dx.doi.org/10.1371/journal.pone.0121620 Text en © 2015 Droppa et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Droppa, Michal
Tschernow, Dimitri
Müller, Karin A. L.
Tavlaki, Elli
Karathanos, Athanasios
Stimpfle, Fabian
Schaeffeler, Elke
Schwab, Matthias
Tolios, Alexander
Siller-Matula, Jolanta M.
Gawaz, Meinrad
Geisler, Tobias
Evaluation of Clinical Risk Factors to Predict High On-Treatment Platelet Reactivity and Outcome in Patients with Stable Coronary Artery Disease (PREDICT-STABLE)
title Evaluation of Clinical Risk Factors to Predict High On-Treatment Platelet Reactivity and Outcome in Patients with Stable Coronary Artery Disease (PREDICT-STABLE)
title_full Evaluation of Clinical Risk Factors to Predict High On-Treatment Platelet Reactivity and Outcome in Patients with Stable Coronary Artery Disease (PREDICT-STABLE)
title_fullStr Evaluation of Clinical Risk Factors to Predict High On-Treatment Platelet Reactivity and Outcome in Patients with Stable Coronary Artery Disease (PREDICT-STABLE)
title_full_unstemmed Evaluation of Clinical Risk Factors to Predict High On-Treatment Platelet Reactivity and Outcome in Patients with Stable Coronary Artery Disease (PREDICT-STABLE)
title_short Evaluation of Clinical Risk Factors to Predict High On-Treatment Platelet Reactivity and Outcome in Patients with Stable Coronary Artery Disease (PREDICT-STABLE)
title_sort evaluation of clinical risk factors to predict high on-treatment platelet reactivity and outcome in patients with stable coronary artery disease (predict-stable)
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4370634/
https://www.ncbi.nlm.nih.gov/pubmed/25799149
http://dx.doi.org/10.1371/journal.pone.0121620
work_keys_str_mv AT droppamichal evaluationofclinicalriskfactorstopredicthighontreatmentplateletreactivityandoutcomeinpatientswithstablecoronaryarterydiseasepredictstable
AT tschernowdimitri evaluationofclinicalriskfactorstopredicthighontreatmentplateletreactivityandoutcomeinpatientswithstablecoronaryarterydiseasepredictstable
AT mullerkarinal evaluationofclinicalriskfactorstopredicthighontreatmentplateletreactivityandoutcomeinpatientswithstablecoronaryarterydiseasepredictstable
AT tavlakielli evaluationofclinicalriskfactorstopredicthighontreatmentplateletreactivityandoutcomeinpatientswithstablecoronaryarterydiseasepredictstable
AT karathanosathanasios evaluationofclinicalriskfactorstopredicthighontreatmentplateletreactivityandoutcomeinpatientswithstablecoronaryarterydiseasepredictstable
AT stimpflefabian evaluationofclinicalriskfactorstopredicthighontreatmentplateletreactivityandoutcomeinpatientswithstablecoronaryarterydiseasepredictstable
AT schaeffelerelke evaluationofclinicalriskfactorstopredicthighontreatmentplateletreactivityandoutcomeinpatientswithstablecoronaryarterydiseasepredictstable
AT schwabmatthias evaluationofclinicalriskfactorstopredicthighontreatmentplateletreactivityandoutcomeinpatientswithstablecoronaryarterydiseasepredictstable
AT toliosalexander evaluationofclinicalriskfactorstopredicthighontreatmentplateletreactivityandoutcomeinpatientswithstablecoronaryarterydiseasepredictstable
AT sillermatulajolantam evaluationofclinicalriskfactorstopredicthighontreatmentplateletreactivityandoutcomeinpatientswithstablecoronaryarterydiseasepredictstable
AT gawazmeinrad evaluationofclinicalriskfactorstopredicthighontreatmentplateletreactivityandoutcomeinpatientswithstablecoronaryarterydiseasepredictstable
AT geislertobias evaluationofclinicalriskfactorstopredicthighontreatmentplateletreactivityandoutcomeinpatientswithstablecoronaryarterydiseasepredictstable